Skip to main content
Clinical Trials/CTRI/2025/10/096061
CTRI/2025/10/096061
Completed
Phase 2

Combined Effects of Transcranial Direct Current Stimulation and Oral Baclofen on Spasticity and Motor Function in Patients with Spastic Hemiplegia: A Randomized Controlled Trial

KLE Academy of Higher Education and Research1 site in 1 country36 target enrollmentStarted: November 15, 2025Last updated:

Overview

Phase
Phase 2
Status
Completed
Sponsor
KLE Academy of Higher Education and Research
Enrollment
36
Locations
1
Primary Endpoint
Modified Ashworth Scale

Overview

Brief Summary

This Randomized placebo controlled interventional trail aims to evaluate the combined effect of transcranial direct current stimulation (tDCS) and oral Baclofen on spasticity and motor function in individuals with post -stroke spastic hemiplegia. Stroke is a major cause of long-term disability and spasticity significantly limits functional recovery and quality of life. Participants diagnosed with spastic hemiplegia following stroke will be randomly assigned to two groups. The experimental group will receive real tDCS, oral Baclofen, and conventional physiotherapy, while the control group will receive sham (placebo) tDCS along with conventional physiotherapy. The interventions will be administered over a period of 2 weeks. Primary outcome measures will include changes in spasticity assessed by the Modified Ashworth scale and motor function assessed by the Fugl-Meyer Assessment. Secondary outcomes will include Stroke impact scale. This study intends to investigate whether the combination of non invasive brain stimulation and pharmacological treatment provides superior outcomes compared to physiotherapy alone in managing post stroke spasticity.

Study Design

Study Type
Interventional
Allocation
Coin toss, Lottery, toss of dice, shuffling cards etc
Masking
None

Eligibility Criteria

Ages
18.00 Year(s) to 65.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • Subjects with : All genders between the age group of 18 to 65 years of age, Who are willing to participate Diagnosed with first time stroke Ischemic or Hemorrhagic (more than 3months) Spasticity more than 1 plus according to Modified Ashworth Scale in atleast one major upper or lower limb muscle.
  • Consciousness able to follow verbal commands & no hearing disability No other associated traumatic and non traumatic disorder of neurological, musculoskeletal and cardiac system.

Exclusion Criteria

  • Subjects with Severe cognitive impairment Known Allergy or intolerance to Oral Baclofen drug Pregnancy or lactation Sensory disturbances History of seizures or epilepsy Presence of metal implants or electronic devices ( eg: pacemaker, cochlear implants) Currently receiving other spasticity reducing treatment (eg: botulinum toxin , intrathecal baclofen) Other unstable medical conditions.

Outcomes

Primary Outcomes

Modified Ashworth Scale

Time Frame: Modified Ashworth Scale to assess spasticity pre and post 2 week intervention | Fugl meyer assessment Scale | is used to assess motor function pre and post intervention

Fugl meyer assessment Scale

Time Frame: Modified Ashworth Scale to assess spasticity pre and post 2 week intervention | Fugl meyer assessment Scale | is used to assess motor function pre and post intervention

Secondary Outcomes

  • Stroke Impact Scale(Stroke Impact scale assesses physical function , emotion , memory, communication and social participation in stroke survivors pre and post intervention.)

Investigators

Sponsor
KLE Academy of Higher Education and Research
Sponsor Class
Private medical college
Responsible Party
Principal Investigator
Principal Investigator

Dr Raghavendrasingh Dharwadkar

KAHER Institute of Physiotherapy

Study Sites (1)

Loading locations...

Similar Trials